LCI VS RUBY Stock Comparison

Performance

LCI
10/100

LCI returned -74.42% in the last 12 months. Based on the other stocks in its sector with an average return of -23.90%, its performance is below average giving it a grade of 10 of 100.

RUBY
10/100

RUBY returned -98.07% in the last 12 months. Based on the other stocks in it's sector with an average return of -23.41%, it's performance is below average giving it a grade of 10 of 100.

Forecast

LCI
64/100

7 analysts offer 12-month price forecasts for LCI. Together, they have an average target of 0, the most optimistic forecast put LCI at 0 within 12-months and the most pessimistic has LCI at 0.

RUBY

"Forecast" not found for RUBY

Technicals

LCI
21/100

LCI receives a 21 of 100 based on 14 indicators. 3 are bullish, 11 are bearish.

RUBY
11/100

RUBY receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

LCI
10/100

LCI has missed earnings 9 times in the last 20 quarters.

RUBY
10/100

RUBY has missed earnings 10 times in the last 20 quarters.

Profit

LCI
10/100

Out of the last 4 quarters, LCI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

RUBY
10/100

Out of the last 16 quarters, RUBY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

LCI
48/100

LCI has had a lower than average amount of volatility over the last 12 months giving it a grade of 47 of 100.

RUBY
60/100

RUBY has had a higher than average amount of volatility over the last 12 months giving it a grade of 60 of 100.

Sentiment

LCI

"Sentiment" not found for LCI

RUBY
74/100

RUBY had a bullish sentiment score of 73.52% across Twitter and StockTwits over the last 12 months. It had an average of 112.63 posts, 390,651.67 comments, and 275,565.84 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Lannett Company, Inc. Summary

New York Stock Exchange / LCI

Healthcare

Drug Manufacturers—Specialty & Generic

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.

Rubius Therapeutics, Inc Summary

Nasdaq / RUBY

Healthcare

Biotechnology

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio